North to the net outflow of funds for three consecutive weeks, 60% of pharmaceutical stocks were reduced

Pharmaceutical Network February 22 News Spring Festival holiday near the end, after the gathering tomorrow will have to face the A-share market in the north of the data came out, the clock for the first time we sorted out its movements.Unfortunately, before the Spring Festival In the final week, the funds in the north were still outflowed, with about 40% of the stocks being overweight and 60% of the shares being underweight. In the case of pharmaceutical stocks, this is generally the case.

Northbound funds in the first three trading days (Feb. 12-14) a total net outflow of 982 million yuan, compared with the previous week out of billions of sharply reduced the size of the However, the last trading day before the holiday, that is, February 14 The two cities showed a net inflow of the same day, of which the net inflow of Shenzhen 761 million yuan, the Shanghai stock market inflow of 384 million yuan. It seems north of the funds are also bet after the A shares rebound after the stock from the recent data, by the market environment, North funds also showed strong volatility.

From the plate point of view, the motherboard, small board stocks about 43% of the shares obtained jiacang, Entrepreneurship The board is relatively weak, only one-third of the shares were Masukura.The data compared with the previous week also have a greater difference, February 4 - February 9 the week the market plummeted, the GEM favored by the north to the capital, Motherboard attention is relatively weak.

From the individual stocks point of view, about 40% of the shares by the north to the capital increase, nearly Liucheng stocks appear to lighten up in varying degrees.Compared to the share of Masukura stocks compared with the previous week, but declined, but the net capital outflow significantly reduced Reflecting that although the range of stock lighten up, but for individual stocks Masukura efforts to increase, resulting in a net final capital outflow less.

From the industry point of view, holdings of stocks higher in the chemical industry, food and beverage, non-bank finance, utilities, plate over 50% of the net capital inflows. Transportation, electrical equipment, defense more than 70% Standard is lighten up.

Although the pre-holiday medical sector overall pick-up, but North to the plate is still the main lighten up, nearly 6 into the subject shares by foreign holdings of 36 companies whose market capitalization exceeds 100 million yuan, only about one-third Stocks were overweight. Fosun Pharma (39.910, 1.50, 3.91%), Ji Chuan Pharmaceutical (41.700, 0.86, 2.11%), Hualan (25.550, 0.25, 0.99%), East China Pharmaceutical (55.350, 1.57, 2.92 %) 4 stocks Masukura ratio over 3%.

However, compared with the previous two, there are still two different points: First, Hengrui Pharmaceutical (71.930, 0.70, 0.98%), Fosun Pharma and other leading pharmaceutical companies back to the field of vision of foreign investors, showing signs of growth; second, The stock began to substantially lighten up.

Specifically, Hengrui Medicine, the leading drugstore, was continuously increased by 1.96% qoq in the three trading days prior to the holiday and the increase in the number of positions in the 9 stocks with a market capitalization of over RMB10 billion was also at a relatively high level In addition, we will change the other fundamentals stocks combed as follows:

Fosun Pharma announced in succession before the holiday heavy bulletin, February 13, 2018 Company announcement: 1) holding subsidiary Fuhong Hanlin access to the United States Galaxy (the United States biopharmaceutical company focused on growth factors and their receptors Or death receptor.) Exclusive license to exclusively develop and commercialize an innovative monoclonal antibody that acts on death receptor pathways in mainland China, Hong Kong and Macau Special Administrative Regions, and Taiwan. 2) Holding subsidiaries Yellow River Pharmaceutical Amlodipine besylate tablets (5mg) through the generic drug consistency assessment.

Zhongtai Securities believes that Fosun Pharma will introduce innovative monoclonal antibody to the United States to further enrich the pipeline of innovative drugs.Amlodipine is expected to increase its market share significantly through consistency assessment.Amlodipine is suitable for hypertension And coronary heart disease. According to the Mi Net data, 2016 city public hospital Amlodipine besylate market size of about 2.92 billion yuan, of which Pfizer Pharmaceutical holds a 72.07% share of the company subsidiary of Jiangsu Huanghe Pharmaceutical 2017 to do drug Production and sales.Company products for the first of its kind in the same species through the consistent evaluation of varieties, market share has great room for growth.Company is expected to take full advantage of generic drug evaluation of the opportunity to seize new market opportunities.

Hualan recently continued holdings of foreign capital, we have been in the article last week, an analysis of its hot text "under the flu Beijing middle class" brushing friends circle, people's attention to the flu rapidly rising. The company has earlier Layout of the four-flu vaccine, April 28, 2015 has been declared a clinical application, as of February 13 this year has completed the pharmacological toxicology and pharmaceutical review, pending clinical review.Professors predict that, with the high incidence of influenza, Regulators or will speed up the approval process so that products available as soon as possible.According to the agency is expected, the variety of the market space at 1 billion yuan.

3 Tonghua Dongbao (22.800, 0.01, 0.04%)

Tonghua Dongbao also continued to receive foreign capital jiacang since February, CICC recently released research report said that the recent survey of Tonghua Dongbao, that the company short-term systemic risk has affected the stock price has a certain adjustment, the fundamentals are good, the next few Maintain rapid growth in the year there is a strong certainty, to maintain the target price of 27.50 yuan, maintain the recommended evaluation.

It is noteworthy that diving medical (20.830, -0.03, -0.14%), Tiger medicine (34.730, -0.67, -1.89%) positions decreased by more than 10% MoM, only 3 trading days before the holiday under the premise of the lighten-up margin is still larger.In addition, has been favored by foreign investors Shinco Cheng (38.180 , -0.30, -0.78%) also showed signs of substantial lighten up, the company benefited from price hikes in vitamins have been sought after by the funds.

In general, the volatility of northbound funds is relatively large and highly correlated with market trends.

PS: Zhong Zhong's articles are based on industry or company trends capture and analysis, do not constitute investment advice, please be familiar with.

Brokerage China is the new media of the Securities Times, the authoritative media of the securities market. China brokered copyright in the original content published on the platform and reprinted without authorization. Otherwise, the legal liability will be investigated.